Servier snags FDA approval for Voranigo, the 1st targeted therapy for a common type of brain tumor

Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. The approval represents the first major treatment advance in low-grade brain cancer in more than two decades.